Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163501
Status:
COMPLETED
Last Update Posted:
2016-11-30
First Post:
2005-09-12
Brief Title:
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment BY9010M1-404
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide Applied as a Nasal Spray 200 Mcg Once Daily in the Treatment of Perennial Allergic Rhinitis PAR in Patients 12 Years and Older
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo inactive substance nasal spray in relieving symptoms of perennial allergic rhinitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None